CareDx
CDNA | NASDAQ
$73.72
-$4.16 (-5.34%)
At close: Nov 16, 2026, 4:00 PM ET
$73.69
-$0.03 (-0.04%)
After-hours:
Nov 16, 2026, 7:49 PM ET
CareDx Company Profile
Company profile explainedCompany Profile
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
Key Executives
| Name | Position |
|---|---|
| John Walter Hanna Jr. | President, Chief Executive Officer & Director |
| Kashif Rathore | Chief Technology Officer |
| Jeffrey A. Novack | General Counsel & Secretary |
| Jessica Meng | Chief Commercial Officer |
| Jing Huang | Chief Data & Artificial Intelligence Officer |
| Keith S. Kennedy | CFO & COO |
| Marica Grskovic | Chief Strategy Officer |
| Natasha Moshirian Wagner | Vice President of Corporate Communications |
| Nina D. Deka | Head of Investor Relations |
| Robert N. Woodward | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 29, 2026 | 8-K | Current Report |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Sep 16, 2026 | 8-K/A | [Amend] Current Report |
| Sep 15, 2026 | 4 | Filing |
| Sep 15, 2026 | 4 | Filing |
CareDx
| Country | United States |
| IPO Date | Jul 17, 2014 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 763 |
| CEO | John Walter Hanna Jr. |
Contact Details
8000 Marina Boulevard Brisbane,
California 94005 United States
Stock Details
| Ticker Symbol | CDNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001217234 |
| CUSIP Number | 14167L103 |
| ISIN Number | US14167L1035 |
| SIC Code | 8071 |
Recent News
- 10 days ago / businesswire.comCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 11 days ago / zacks.comCareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
- 14 days ago / zacks.comCareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
- 14 days ago / businesswire.comCareDx Announces Third KOAR Analysis Published in Transplantation
- 17 days ago / fool.comWhy CareDx Stock Soared Today
- 18 days ago / seekingalpha.comCareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
- 18 days ago / marketbeat.comWhat CareDx (CDNA) Said on Its Q3 Earnings Call
- 18 days ago / zacks.comCareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
- 22 days ago / zacks.comCareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
- 26 days ago / businesswire.comCareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
Add to Watchlist
Select watchlists to add or remove CDNA